Trial Details
COMPLETEDBasic Information
| Clinical ID | c2267 |
|---|---|
| Identifier | NCT03760003 |
| Trial Title | Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Ulcerative Colitis |
| Interventions | DRUG: ABX464 100 mg|DRUG: ABX464 50 mg|DRUG: ABX464 25 mg|DRUG: Placebo |
Participant Information
| Sponsor | Abivax S.A. |
|---|---|
| City | San Diego |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2019-08-13 |
|---|---|
| Primary Completion Date | 2021-04-01 |
| Completion Date | 2021-04-16 |